FSNUY FRESENIUS SE&CO KGAA SPON ADR EA REP 0.25 ORD SHS
- 7.570
- -0.050-0.66%
FRESENIUS SE&CO KGAA SPON ADR EA REP 0.25 ORD SHS News
Moody's Affirms Fresenius' Rating, Outlook on Improving Profitability
Moody's on Thursday affirmed Fresenius' (FRE.F) long-term issuer and senior unsecured ratings at Baa3, with a stable outlook. The rating confirmation highlights expectations of improvement in the Germ
Fresenius Guidance Lift, Vamed Restructuring in Focus -- Market Talk
0656 GMT - Fresenius's guidance lift and exit from its Vamed unit stood out among first-quarter results that beat market expectations, Jefferies analysts say. "While the market understood guidance to
Fresenius Lifts Guidance On Net Profit Beat
By Helena Smolak Fresenius lifted its full-year guidance on rising net profit that beat expectations in the first quarter, which was boosted by an improved performance of its core businesses Freseniu
Fresenius: Vamed's Hospital Services Unit to Be Transferred to Fresenius Group
Fresenius: Vamed's Hospital Services Unit to Be Transferred to Fresenius Group
Fresenius: Vamed's International Project Business to Gradually Be Scaled Back
Fresenius: Vamed's International Project Business to Gradually Be Scaled Back
Fresenius to Sell Vamed's Operations in Austria to Consortium
Fresenius to Sell Vamed's Operations in Austria to Consortium
Fresenius Exits Vamed
Fresenius Exits Vamed
Analysts Saw Fresenius 1Q Revenue At EUR5.69B
Analysts Saw Fresenius 1Q Revenue At EUR5.69B
Fresenius 1Q EBIT EUR559M
Fresenius 1Q EBIT EUR559M
Fresenius Raises FY24 View of Organic Group Rev Growth to 4%-7% >FRE.XE
Fresenius Raises FY24 View of Organic Group Rev Growth to 4%-7% >FRE.XE
PRESS RELEASE: Eqs-Adhoc: Fresenius Raises Outlook For Fiscal Year 2024
EQS-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Change in Forecast Fresenius SE & Co. KGaA: Fresenius raises outlook for fiscal year 2024 07-May-2024 / 21:19 CET/CEST Disclosure of an inside inform
Fresenius' Disposal of Part of Its Rehabilitation Business Seems Positive -- Market Talk
0819 GMT - Fresenius' smonetization of its non-core assets to cut debt should be welcomed by investors, Berenberg analysts Victoria Lambert and Tom Jones say in a note. The German health care firm's d
Fresenius: Business Has an Enterprise Value of EUR853M
Fresenius: Business Has an Enterprise Value of EUR853M
Fresenius: Agreement Is for the Sale of Vamed's Rehabilitation Business
Fresenius: Agreement Is for the Sale of Vamed's Rehabilitation Business
Fresenius: Closing Is Expected in 2H
Fresenius: Closing Is Expected in 2H
Fresenius: Divestment Is Part of the Company's Portfolio Optimization
Fresenius: Divestment Is Part of the Company's Portfolio Optimization
Fresenius: PAI Partners Will Become Majority Owner of Vamed With 67%
Fresenius: PAI Partners Will Become Majority Owner of Vamed With 67%
Fresenius Will Keep a 33%
Fresenius Will Keep a 33%
Fresenius: Transaction Is Subject to Regulatory Approval
Fresenius: Transaction Is Subject to Regulatory Approval
Fresenius Completes Peru Divestment
Fresenius Completes Peru Divestment
Analysis
Price Target
No Data
